Cetera Investment Advisers Acquires New Position in Guardant Health, Inc. $GH

Key Points

• Cetera Investment Advisers has established a new investment in Guardant Health, acquiring 4,961 shares valued at approximately $211,000 during the first quarter.
• Guardant Health reported better-than-expected earnings of ($0.44) per share, surpassing analysts' predictions of ($0.52), with revenue increasing by 31% year-over-year to $232.09 million.
• Analysts have a consensus “Buy” rating for Guardant Health, with several firms raising their price targets, indicating positive market sentiment towards the company's stock.

Cetera Investment Advisers bought a new stake in Guardant Health, Inc. (NASDAQ:GH - Free Report) in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 4,961 shares of the company's stock, valued at approximately $211,000.

A number of other institutional investors have also added to or reduced their stakes in GH. Two Sigma Advisers LP grew its stake in Guardant Health by 96.7% in the fourth quarter. Two Sigma Advisers LP now owns 2,315,600 shares of the company's stock valued at $70,742,000 after acquiring an additional 1,138,300 shares during the period. Point72 Asset Management L.P. bought a new position in shares of Guardant Health in the 4th quarter worth $26,673,000. Emerald Advisers LLC acquired a new stake in Guardant Health in the 1st quarter valued at $22,639,000. Two Sigma Investments LP increased its stake in Guardant Health by 38.5% during the 4th quarter. Two Sigma Investments LP now owns 1,890,714 shares of the company's stock valued at $57,761,000 after purchasing an additional 525,368 shares in the last quarter. Finally, Principal Financial Group Inc. increased its stake in Guardant Health by 4,838.8% during the 1st quarter. Principal Financial Group Inc. now owns 498,129 shares of the company's stock valued at $21,220,000 after purchasing an additional 488,043 shares in the last quarter. 92.60% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Guardant Health

In other news, Director Ian T. Clark sold 6,672 shares of the stock in a transaction that occurred on Tuesday, June 17th. The shares were sold at an average price of $48.38, for a total transaction of $322,791.36. Following the completion of the transaction, the director directly owned 9,851 shares of the company's stock, valued at $476,591.38. This represents a 40.38% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Amirali Talasaz sold 100,000 shares of the firm's stock in a transaction that occurred on Tuesday, July 1st. The stock was sold at an average price of $50.88, for a total transaction of $5,088,000.00. Following the sale, the chief executive officer owned 1,971,830 shares of the company's stock, valued at approximately $100,326,710.40. The trade was a 4.83% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 235,542 shares of company stock valued at $11,852,491 in the last three months. 6.10% of the stock is owned by corporate insiders.

Guardant Health Stock Performance

Shares of GH traded up $0.48 on Monday, reaching $61.88. 1,523,316 shares of the company's stock traded hands, compared to its average volume of 3,352,199. The stock's 50 day simple moving average is $50.51 and its two-hundred day simple moving average is $46.08. Guardant Health, Inc. has a 52-week low of $20.14 and a 52-week high of $62.81.

Guardant Health (NASDAQ:GH - Get Free Report) last announced its quarterly earnings data on Wednesday, July 30th. The company reported ($0.44) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.52) by $0.08. The business had revenue of $232.09 million during the quarter, compared to the consensus estimate of $211.19 million. During the same quarter last year, the company earned ($0.84) EPS. The firm's revenue for the quarter was up 31.0% compared to the same quarter last year. Guardant Health has set its FY 2025 guidance at EPS. As a group, sell-side analysts forecast that Guardant Health, Inc. will post -2.9 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on GH. Raymond James Financial raised their price objective on shares of Guardant Health from $59.00 to $61.00 and gave the company an "outperform" rating in a research note on Thursday, July 31st. Mizuho upped their target price on shares of Guardant Health from $60.00 to $65.00 and gave the stock an "outperform" rating in a report on Friday, June 13th. TD Securities lifted their price target on Guardant Health from $56.00 to $60.00 and gave the company a "buy" rating in a research note on Thursday, May 1st. Barclays boosted their price objective on Guardant Health from $55.00 to $60.00 and gave the stock an "overweight" rating in a report on Thursday, May 1st. Finally, Canaccord Genuity Group raised their target price on Guardant Health from $60.00 to $65.00 and gave the company a "buy" rating in a report on Thursday, May 1st. One equities research analyst has rated the stock with a Strong Buy rating and sixteen have given a Buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Buy" and an average target price of $57.50.

Guardant Health Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.